Kangtai biological: It is expected that the net profit will decrease by 63.8% to 75.7% in 2025 compared to the same period.

Kangtai Biotech announced that it is expected that the net profit attributable to the mother in 2025 will be between RMB 49 million and RMB 73 million, a year-on-year decrease of 63.8% to 75.7%. During the reporting period, the company strengthened the market promotion and bidding qualification work of new products such as freeze-dried human rabies vaccine and attenuated live varicella vaccine, and strived to improve the market share of the company's core products. At the same time, the company continued to advance its internationalization strategy, steadily expanding its overseas business layout. During the reporting period, the company's operating income slightly increased compared to the same period of the previous year, with overseas business achieving revenue of RMB 98.8353 million, an increase of 859.4% year-on-year, and the international business expansion made some progress.